Medtronic’s $43 billion deal to acquire Covidien and move to Ireland for tax purposes has heated up the “corporate inversion” game and will likely embolden more U.S. companies to seek deals to capture savings while the law allows.
Medtronic’s $43 billion deal to acquire Covidien and move to Ireland for tax purposes has heated up the “corporate inversion” game and will likely embolden more U.S. companies to seek deals to capture savings while the law allows.